ReviewiScience2026
Rediscovering cytisine: Why the WHO's decision matters for global public health.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Smoking cessation in emergency departments: a reality check.Internal and emergency medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, the World Health Organization (WHO) announced the inclusion of cytisine in its Model List of Essential Medicines (EMLs). Owing to its efficacy, tolerability profile, and low cost, cytisine represents a valuable addition to the smoking cessation toolkit. This followed approval by the UK MHRA, with regulatory review by the US FDA in process. However, this milestone came over half a century after an initial large-scale randomized controlled trial demonstrated its efficacy. The recognition of cytisine is both a triumph for global health equity and an indictment of the political, economic, and scientific inertia that kept this life-saving treatment in the shadows for more than 50 years. This commentary reviews the history of cytisine, the scientific evidence behind its efficacy, the structural forces that delayed its global recognition, and why its addition to the WHO's EML matters for public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.